This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A critical government advisory committee charged with charting U.S. vaccination policy appears to be atrophying, jeopardizing timely decision-making on how vaccines should be used in this country. The Advisory Committee on Immunization Practices, which has in recent years been a 15-person panel, has eight vacancies — one of which dates back more than a year.
Three years ago, Jamie Lin, an early-career nephrologist at MD Anderson Cancer Center, made findings that could potentially help both save the kidneys of cancer patients and propel her career as a physician-scientist hoping to one day run her own lab. It was a promising start, but that’s when Lin says one of the Texas institute’s most powerful researchers interfered.
Thursday, when senators questioned three Big Pharma CEOs about the high price of drugs in the U.S., Health, Education, Labor and Pensions (HELP) committee chairman Bernie Sanders, I-Vermont, put th | CEOs from Bristol Myers Squibb, Johnson & Johnson and Merck faced tough questions from senators on why prices for drugs in the U.S. exceed those in other countries.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
People receiving a double dose of naloxone are no more likely to survive an opioid overdose than people receiving a standard, 4-milligram nasal spray, according to a new study. The new paper , published Thursday in the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report, showed no significant difference in survival rates between people who were revived using 4- and 8-milligram sprays of naloxone, commonly known by the brand name Narcan.
Explore the commercial research landscape in the UK and the evolution of the National Institute for Health Research (NIHR) through an informative webinar.
With $45.8 billion in 2023 revenues, AstraZeneca has met the $45 billion-by-2023 goal CEO Pascal Soriot established in 2014 when he was fending off a takeover bid from Pfizer. | AstraZeneca has met the $45 billion-by-2023 revenue goal that CEO Pascal Soriot established in 2014. But questions have emerged for one of the company's key growth drivers.
This agent can prevent the depletion of heparan sulphate in the endothelial glycocalyx layer of endothelial cells, ultimately protecting against vision loss and renal failure caused by diabetes.
The study authors noted that further research with larger populations should be conducted to boost the reliability and generalizability of the results.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The world may be getting over the idea that men are from Mars and women from Venus , but public perception still holds that testosterone is the male hormone , and estrogen, the female. That can make the following fact a little puzzling: There is more testosterone than estrogen in a premenopausal woman’s body. Testosterone levels decrease with time and reach especially low values after menopause, which can lead to loss of bone density, lower energy, and depression.
Enrollment in individual market plans continues to grow, with a record high of 21.3 million people signing up for plans during the most recent open enrollment period. | CEO Mark Bertolini told investors that Oscar “closed out 2023 with another strong quarter, driving financial performance for the full year.
LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly. Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals.
Epidemiological studies can often throw out intriguing and sometimes erroneous correlations between a variable and a disease, but UK scientists say a finding that Alzheimer’s disease seems to be less common in Viagra users warrants further investigation.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study. A looming test for neoantigen cancer vaccines Before the end of the quarter, Gritstone Bio will release preliminary results from a randomized, Phase 2 clinical trial investigating a personalized therapeutic cancer vaccine in microsatellite-stable colon cancer, a type of “immunologically cold” tumor that i
Stay up to date with the latest updates in the world of clinical trials. This week's highlights include Bayer's new study on aflibercept, BioNTech's groundbreaking research, and the exciting developments from Duality Bio. Get all the important information here.
Has AI really solved biology? What can machines teach us about medicine? And what’s a digital twin? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technology to find new drug targets, design therapies, and improve clinical trials.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
WASHINGTON — Call it Sen. Bernie Sanders’ prescription drug pricing theater. The hearing, featuring Merck CEO Robert Davis, Johnson and Johnson CEO Joaquin Duato, and Bristol Myers Squibb CEO Chris Boerner, was designed to draw public interest, and in that respect, it worked. The wood-paneled hearing room in a Senate office building was standing room only, with an overflow room prepared.
Tiene Bauters, PharmD PhD, Pharmacy Department , Ghent University Hospital in Belgium, offers her take on what’s hot on the horizon for hospital pharmacy in 2024. We have just stepped into a new year, and it is already clear that the pharmacy landscape is set to experience significant innovations and challenges over the coming weeks and months. These will undoubtedly present great opportunities for hospital pharmacists and their teams.
China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by subcutaneous injection.
Roughly an eon ago in the pharma industry (read: 20 years), Sandoz carved out a sizable generics foothold through dual mergers with Germany’s Hexal and U.S.-based Eon Labs. | Nearly 20 years after Sandoz carved out a sizable generics foothold via dual mergers with Germany’s Hexal and U.S.-based Eon Labs, the Swiss manufacturing giant is mothballing one of the latter company’s main manufacturing sites.
BioNTech has taken a $200 million stake in Autolus in a private placement that will allow it to tap into the UK company’s manufacturing capacity for CAR-T therapies
WASHINGTON — Rep. Cathy McMorris Rodgers, the chair of a crucial House committee that handles health care issues, plans to leave Congress at the end of the year, she announced Thursday. It will be a major shakeup for a panel already ravaged by Republican retirements. Reps. Michael Burgess (R-Texas), Larry Bucshon (R-Ind.), Jeff Duncan (R-S.C.), Debbie Lesko (R-Ariz.), Greg Pence (R-Ind.) and Kelly Armstrong (R-N.D.) are all leaving at the end of this Congress, too.
Astellas appoints Nick Eshkenazi as chief digital and transformation officer (CTDO), the first time the pharma has included a digital role in its top management team
By some measures, private equity investment lagged in 2023, a year marked by growing distress and high-profile downfalls among private equity-backed health care companies. Even so, three sectors still managed to see strong deal flow and prices: med spa, cardiology, and clinical trial sites, according to a new PitchBook report analyzing private equity investments in health care services in 2023.
Eczema is the second most common skin condition in the United States, affecting more than 31 million Americans. The term “eczema” refers to a group of inflammatory skin conditions that cause dry, itchy skin. Of the seven types of eczema, atopic dermatitis is the most common—up to 25% of children and 3% of adults develop it. While it’s not contagious, eczema rashes, scaly patches, and blisters can cause discomfort and pain.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with the latest Senate harangue for the drug industry, green shoots in biotech sentiment, and the potential of a gene therapy eye drop.
103
103
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content